At3g17010 Antibody

What is the At3g17010 antibody and what protein does it target?

The At3g17010 antibody is a rabbit-derived polyclonal IgG antibody that specifically recognizes the REM22 protein (UniProt: Q9LSP6) encoded by the At3g17010 gene in Arabidopsis thaliana. This antibody targets a recombinant form of the At3g17010 protein and has been affinity-purified to enhance specificity . The target protein functions as a B3-type transcription factor involved in early stamen development and is regulated by the floral homeotic factor AGAMOUS . Understanding this antibody's target is essential for properly interpreting experimental results in developmental plant biology research.

What are the validated applications for the At3g17010 antibody?

According to product specifications, the At3g17010 antibody has been validated for use in Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB) applications . These techniques allow for both quantitative and qualitative analysis of REM22 protein expression. While the antibody shows reliable performance in these applications, researchers should conduct preliminary validation experiments in their specific experimental systems before proceeding with larger studies. This validation should include appropriate positive controls (using the provided antigen) and negative controls (using the provided pre-immune serum) to confirm specificity.

How is the gene expression pattern of At3g17010 characterized in plant development?

The At3g17010 gene exhibits a specific spatial and temporal expression pattern during plant development. In situ hybridization experiments have revealed that At3g17010 is predominantly expressed in emerging stamen primordia during early flower development, before the formation of sporogenous tissues . The gene has been identified as differentially expressed in the apetala3 (ap3) mutant but not in sporocyteless/nozzle (spl/nzz) or male sterile1 (ms1) mutants, further confirming its role in early stamen development . Some genes have been found to have partially overlapping expression patterns with At3g17010, suggesting potential functional redundancy in developmental pathways. Understanding this expression pattern is crucial for designing experiments that target specific developmental stages.

What storage and handling conditions are recommended for the At3g17010 antibody?

The At3g17010 antibody should be stored at either -20°C or -80°C to maintain its activity and specificity . For routine use, aliquoting the antibody to minimize freeze-thaw cycles is strongly recommended, as repeated freezing and thawing can lead to protein denaturation and reduced antibody performance. When working with the antibody, keep it on ice and use appropriate buffers as recommended by the supplier. The provided positive control antigen (200μg) and negative control pre-immune serum (1ml) should be stored under the same conditions. Always include these controls in experimental designs to ensure result validity and to help troubleshoot potential issues with antibody functionality.

How can epitope mapping be performed to determine the specific binding regions of the At3g17010 antibody?

To perform epitope mapping for the At3g17010 antibody, researchers can employ several complementary approaches. Similar to techniques used in other antibody research, cryo-electron microscopy can be utilized to visualize antibody-antigen complexes at high resolution . Additionally, researchers can create truncated versions of the recombinant At3g17010 protein to identify which regions maintain antibody recognition. Peptide array analysis, where overlapping peptides spanning the entire At3g17010 sequence are synthesized and tested for antibody binding, provides a systematic approach to identify specific binding epitopes. Computational analysis of antibody-antigen interaction can supplement experimental data, particularly for predicting conformational epitopes. Understanding the specific epitopes recognized by the antibody is crucial for interpreting cross-reactivity patterns and designing competition assays.

What strategies can be employed to improve the specificity and sensitivity of At3g17010 antibody for detecting low abundance transcription factors?

Enhancing the detection of low abundance transcription factors like REM22 requires specialized approaches. Signal amplification techniques such as tyramide signal amplification (TSA) can significantly increase sensitivity in immunohistochemistry and immunofluorescence applications. For Western blot applications, using high-sensitivity chemiluminescent substrates and digital imaging systems can improve detection limits. Antibody affinity purification against the specific immunogen can reduce background and enhance specificity. Pre-adsorption of the antibody with plant extracts from knockout or knockdown lines lacking At3g17010 expression can further reduce non-specific binding. Additionally, researchers might consider employing proximity ligation assays (PLA) for detecting protein-protein interactions involving REM22, which provides exceptional sensitivity through rolling circle amplification of detection signals. These approaches must be carefully optimized for each experimental system to maintain specificity while improving sensitivity.

How can researchers design experiments to investigate the functional redundancy between At3g17010 and related B3-type transcription factors?

To investigate potential functional redundancy between At3g17010 and related B3-type transcription factors (particularly At5g09780, which shows similar expression patterns ), researchers should employ a multi-faceted approach. First, comprehensive expression profiling using RNA-seq or microarray analysis can identify transcription factors with overlapping spatiotemporal expression patterns. Next, generating single and combinatorial knockout/knockdown mutants using CRISPR/Cas9 or RNAi approaches allows for phenotypic comparison. ChIP-seq (Chromatin Immunoprecipitation followed by sequencing) using the At3g17010 antibody can identify genome-wide binding sites of the transcription factor, which can then be compared with binding profiles of related factors. Protein-protein interaction studies using co-immunoprecipitation with the At3g17010 antibody followed by mass spectrometry can reveal potential heterodimerization between related transcription factors. Finally, complementation experiments where related B3-type transcription factors are expressed under the At3g17010 promoter in At3g17010 knockout plants can directly test functional redundancy.

What approaches can be used to characterize post-translational modifications of the At3g17010 protein using the available antibody?

Characterizing post-translational modifications (PTMs) of At3g17010 requires specialized immunoprecipitation-based approaches. Researchers can immunoprecipitate the native protein using the At3g17010 antibody followed by mass spectrometry analysis to identify PTMs such as phosphorylation, acetylation, and ubiquitination. For phosphorylation-specific studies, researchers can use Phos-tag™ gels in Western blot analysis with the At3g17010 antibody to separate phosphorylated from non-phosphorylated forms of the protein. Co-immunoprecipitation studies can identify enzymes responsible for adding or removing PTMs. For temporal dynamics of PTMs during development, researchers can perform immunoprecipitation with the At3g17010 antibody from plant tissues at different developmental stages. Additionally, comparing PTM patterns between wild-type and various mutant backgrounds can provide insights into the regulatory mechanisms controlling At3g17010 function. Understanding these modifications is crucial for deciphering the regulatory mechanisms controlling transcription factor activity during stamen development.

What optimization strategies should be implemented when using At3g17010 antibody for Western blot analysis of plant tissues?

Optimizing Western blot protocols for the At3g17010 antibody requires careful consideration of several parameters. First, ensure complete protein extraction from plant tissues using appropriate extraction buffers containing protease inhibitors to prevent degradation of the target transcription factor. For membrane transfer, use PVDF membranes rather than nitrocellulose due to their higher protein binding capacity and mechanical strength. Optimize blocking conditions by testing different blocking agents (e.g., BSA, non-fat milk) at various concentrations (3-5%) to minimize background while maintaining specific signal. Determine the optimal antibody dilution through a titration experiment, typically starting with a 1:500 to 1:2000 range for primary antibody incubation. Include the provided positive control antigen (recombinant At3g17010) as a reference standard . Extend the primary antibody incubation period (overnight at 4°C) to enhance sensitivity for detecting low-abundance transcription factors. Use a high-sensitivity chemiluminescent substrate system for detection, with exposure time optimization. Always include a loading control (e.g., actin or tubulin) to normalize protein expression levels across samples.

How can chromatin immunoprecipitation (ChIP) protocols be adapted for use with the At3g17010 antibody?

Adapting ChIP protocols for use with the At3g17010 antibody requires several specific considerations. Begin with optimized crosslinking conditions, testing both formaldehyde concentrations (1-1.5%) and crosslinking times (10-20 minutes) to effectively capture transcription factor-DNA interactions without over-fixation. Use a two-step chromatin shearing approach, combining enzymatic digestion with brief sonication to generate DNA fragments of 200-500 bp. For immunoprecipitation, pre-clear the chromatin with protein A/G beads and pre-immune serum (provided with the antibody kit) before adding the At3g17010 antibody. Optimize antibody amount through titration experiments, typically using 2-10 μg per ChIP reaction. Include appropriate controls: input chromatin (pre-immunoprecipitation sample), IgG control, and ideally a positive control region known to be bound by At3g17010 or related B3-type transcription factors. For plant ChIP applications, modify washing buffers to contain plant-specific detergents and salt concentrations. Finally, validate ChIP-seq results using ChIP-qPCR on selected genomic regions before proceeding to genome-wide analysis.

What immunohistochemistry and immunofluorescence protocols are recommended for studying At3g17010 localization in plant tissues?

For effective immunolocalization of At3g17010 in plant tissues, several tissue-specific adaptations are necessary. Begin with proper tissue fixation using 4% paraformaldehyde in PBS with vacuum infiltration to ensure thorough penetration. For floral tissues, extend fixation time to ensure complete penetration while avoiding overfixation. Following fixation, perform a graded ethanol dehydration series before paraffin embedding and sectioning. For antigen retrieval, use citrate buffer (pH 6.0) with controlled heating to unmask antigenic sites without damaging tissue morphology. Block tissues with 3-5% BSA containing 0.1% Triton X-100 to reduce background while allowing antibody penetration. Apply primary At3g17010 antibody at optimized dilutions (typically 1:100 to 1:500) and incubate overnight at 4°C. For visualization, use fluorophore-conjugated secondary antibodies (anti-rabbit IgG) for immunofluorescence or HRP-conjugated antibodies with DAB substrate for light microscopy. Counterstain with DAPI to visualize nuclei and confirm nuclear localization of the transcription factor. Include controls using pre-immune serum to assess background staining levels . For tissues with high autofluorescence, consider using Sudan Black B treatment or employing spectral unmixing during image acquisition.

How should researchers approach validation experiments to confirm At3g17010 antibody specificity?

A comprehensive validation strategy for the At3g17010 antibody should employ multiple complementary approaches. First, conduct Western blot analysis using the provided positive control antigen (recombinant At3g17010 protein) and pre-immune serum as negative control . Compare protein detection patterns between wild-type Arabidopsis tissues and At3g17010 knockout or knockdown lines, looking for reduced or absent signal in mutant tissues. Perform peptide competition assays by pre-incubating the antibody with excess antigen before application to samples, which should diminish specific signals. Test cross-reactivity against related B3-type transcription factors by examining tissues with differential expression of these proteins. Validate subcellular localization patterns observed in immunostaining by comparison with fluorescent protein fusions of At3g17010 expressed in the same tissue types. Perform immunoprecipitation followed by mass spectrometry to confirm that the antibody captures the intended target protein. Document all validation results thoroughly, including experimental conditions, controls, and quantitative assessments of specificity and sensitivity to establish confidence in the antibody's performance characteristics.

How can researchers address potential cross-reactivity issues with the At3g17010 antibody?

Managing cross-reactivity concerns with the At3g17010 antibody requires systematic troubleshooting approaches. Begin by identifying potential cross-reactive proteins through sequence alignment of At3g17010 with related B3-type transcription factors, particularly At5g09780 which shares expression pattern similarity . Pre-absorb the antibody with recombinant proteins or tissue extracts from plants expressing these related proteins but lacking At3g17010 expression. Increase washing stringency in immunoblotting and immunoprecipitation protocols by using higher salt concentrations or mild detergents. Perform Western blot analysis across multiple plant tissues and developmental stages to create a comprehensive reactivity profile, comparing this with known expression patterns of At3g17010 and related transcription factors. Consider epitope mapping to determine which regions of the protein are recognized by the antibody, which can help predict potential cross-reactivity. For critical experiments, validate findings using orthogonal methods such as mass spectrometry or targeted genetic approaches. Document all cross-reactivity testing systematically to establish the specific conditions under which the antibody performs optimally.

What statistical approaches are recommended for analyzing experimental data generated using the At3g17010 antibody?

For robust statistical analysis of At3g17010 antibody data, implement multi-layered quantitative approaches. For Western blot densitometry, use specialized software (e.g., ImageJ) to quantify band intensities, normalizing to appropriate loading controls and analyzing with ANOVA followed by post-hoc tests for multi-group comparisons. For immunofluorescence quantification, measure fluorescence intensity across multiple biological replicates (n≥3) and technical replicates (n≥3), analyzing pixel intensity distributions rather than means alone. For ChIP-seq data, utilize specialized statistical frameworks such as MACS2 for peak calling, with appropriate false discovery rate (FDR) thresholds (typically q<0.05). Implement differential binding analysis using DESeq2 or edgeR when comparing ChIP-seq data across conditions. For all experiments, calculate appropriate effect sizes and confidence intervals rather than relying solely on p-values. Account for batch effects in experimental design and statistical analysis. When analyzing developmental time-series data, consider applying repeated measures ANOVA or linear mixed models. Present all quantitative results with appropriate visualization methods that accurately represent data distributions, such as violin plots or cumulative distribution functions rather than simple bar graphs.

How can researchers integrate data from At3g17010 antibody experiments with other molecular biology techniques to build comprehensive models of transcription factor function?

Creating an integrated model of At3g17010 function requires synthesizing data from multiple experimental approaches. Begin by mapping genome-wide binding sites through ChIP-seq with the At3g17010 antibody, then correlate these sites with transcriptome changes in At3g17010 mutant plants using RNA-seq to identify direct transcriptional targets. Integrate protein-protein interaction data from co-immunoprecipitation experiments using the At3g17010 antibody followed by mass spectrometry to identify cofactors and regulatory partners. Compare this interactome with those of related B3-type transcription factors to identify unique and shared interactions . Incorporate tissue-specific and developmental stage-specific expression data derived from immunohistochemistry with the At3g17010 antibody. Apply network analysis algorithms to construct gene regulatory networks centered on At3g17010, incorporating both direct targets and indirect effects. Use machine learning approaches to identify regulatory motifs in ChIP-seq datasets and predict additional target genes. Validate key model predictions through targeted genetic experiments such as creating reporter constructs driven by identified regulatory elements. Present the integrated model using appropriate visualization software that captures the temporal and spatial dynamics of At3g17010 function during plant development.

What approaches are recommended for resolving contradictory results when using the At3g17010 antibody across different experimental platforms?

When encountering contradictory results with the At3g17010 antibody across different experimental approaches, implement a structured troubleshooting framework. First, carefully document all experimental conditions, including antibody lot numbers, dilutions, incubation times, buffer compositions, and sample preparation methods to identify potential variables contributing to discrepancies. Test alternative epitope exposure methods for each experimental platform, as the accessibility of the antibody target may differ between applications. Compare results with orthogonal methods that don't rely on the antibody, such as RNA expression analysis or transgenic lines expressing tagged versions of At3g17010. Consider the potential impact of post-translational modifications on antibody recognition, which may vary across tissue types or experimental conditions. Evaluate whether related transcription factors might be differentially expressed across the experimental systems, leading to variable cross-reactivity profiles. Consult with other researchers working with plant transcription factor antibodies to identify common technical challenges. When reporting results, transparently document all contradictory findings and the approaches used to resolve them, acknowledging any remaining uncertainties. This comprehensive troubleshooting approach ensures that apparent contradictions become opportunities for deeper methodological understanding.

How might emerging antibody engineering technologies be applied to enhance the specificity and utility of At3g17010 antibodies?

The field of antibody engineering offers promising approaches for next-generation At3g17010 research tools. Adapting the "sweeping antibody" technology, which incorporates pH-dependent antigen binding properties, could enhance the ability to isolate and concentrate low-abundance transcription factors from plant tissues . Implementation of structure-guided antibody engineering, similar to approaches used for agonist antibodies, could create variants with improved specificity for distinguishing between closely related B3-type transcription factors . Developing biepitopic antibody formats that simultaneously target two distinct regions of the At3g17010 protein could dramatically enhance specificity while maintaining high affinity. Single-domain antibody fragments derived from the existing polyclonal preparation could provide improved tissue penetration for immunohistochemistry applications. Integration of computational antibody design approaches with experimentally determined structural information about At3g17010 could lead to rationally designed antibodies with optimal binding properties . These advanced engineering approaches could transform At3g17010 research by providing tools that overcome current limitations in specificity, sensitivity, and application versatility.

What novel applications of the At3g17010 antibody could advance understanding of plant development regulatory networks?

Innovative applications of the At3g17010 antibody could significantly expand our understanding of plant developmental regulation. Adapting CUT&RUN or CUT&Tag technologies for use with the At3g17010 antibody would provide higher resolution mapping of transcription factor binding sites with reduced background compared to traditional ChIP-seq. Implementing Proximity Labeling approaches, where the At3g17010 antibody is conjugated to enzymes like BioID or APEX2, would allow identification of proteins that transiently interact with At3g17010 in living plant cells. Developing antibody-based live-cell imaging approaches through creation of fluorophore-conjugated Fab fragments of the At3g17010 antibody could enable real-time visualization of transcription factor dynamics during flower development. Applying single-cell technologies, such as using the antibody for intracellular protein staining in protoplasts followed by single-cell sequencing, would reveal cell type-specific functions of At3g17010. Implementing systems biology approaches that integrate antibody-derived data on protein levels, interactions, and chromatin binding with transcriptomic and epigenomic datasets would create comprehensive models of regulatory network function during stamen development. These cutting-edge applications would transform static understanding of transcription factor function into dynamic models of developmental regulation.